All News
Inebilizumab for Treatment of IgG4-Related Disease
Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.
Phase 2b Study of Ianalumab in Sjögren's
A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
Read Article
DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg https://t.co/eSjYCnu02Y
Dr. John Cush RheumNow ( View Tweet)
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
The issues surrounding publication bias are real.
https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H
Dr. John Cush RheumNow ( View Tweet)
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC
Dr. John Cush RheumNow ( View Tweet)
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/8RbSnhS3vl https://t.co/NdRIA4oREr
Dr. John Cush RheumNow ( View Tweet)
J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa
Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju
Dr. John Cush RheumNow ( View Tweet)
In a phase II DBRPCT, Cenerimod (sphingosine-1-phosphate recptr modulator) was not shown effective (vs PBO) at 12 mos in active, SLE pts. CARE study enrolled 427 SLE pts who were randomized to Placebo or 3 different doses of CEN - primary endpoint was not met.… https://t.co/AR6NsEsv8S https://t.co/i89ANl5dai
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush RheumNow ( View Tweet)
Worried about CV Risk and JAKi? What about the Steroids?
Dr. David Liew discusses abstracts 1981 and 2673, presented at #ACR24
https://t.co/OkMgIqxl2A https://t.co/1DVapGcWUn
Dr. John Cush RheumNow ( View Tweet)
Is Frequent Lab Monitoring Necessary?
Dr. Bella Mehta discusses abstract 2619, Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients, presented at #ACR24.
https://t.co/vwPueeAVhO https://t.co/5wyTahjMAu
Dr. John Cush RheumNow ( View Tweet)
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists won the Nobel Prize for discovering steroids, initially hailed as a "miracle cure" for RA. However, within a year, unrelated side effects like pain and fatigue emerged. Despite these issues,… https://t.co/dQEjXzxU0U https://t.co/NqyZHfBiId
Dr. John Cush RheumNow ( View Tweet)
Cumulative Steroid Use and Cardiovascular Events
Dr. Mrinalini Dey abstract 1719, Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study, presented at #ACR24.… https://t.co/DqkDgOwsP9 https://t.co/RXRU05UPoh
Dr. John Cush RheumNow ( View Tweet)
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush RheumNow ( View Tweet)
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow ( View Tweet)
Where there’s smoke, there’s flare: how pollution fuels RA
The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24
https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa
Dr. John Cush RheumNow ( View Tweet)
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush RheumNow ( View Tweet)
